


## Data Sheet

<b>Product Name:</b>	Veledimex (S enantiomer)
<b>Cat. No.:</b>	CS-6930
<b>CAS No.:</b>	1093131-03-3
<b>Molecular Formula:</b>	C <sub>27</sub> H <sub>38</sub> N <sub>2</sub> O <sub>3</sub>
<b>Molecular Weight:</b>	438.60
<b>Target:</b>	Cytochrome P450; Interleukin Related
<b>Pathway:</b>	Immunology/Inflammation; Metabolic Enzyme/Protease
<b>Solubility:</b>	10 mM in DMSO



### BIOLOGICAL ACTIVITY:

Veledimex S enantiomer is the S enantiomer of veledimex. Veledimex is an oral activator ligand for a proprietary gene therapy promoter system, and a moderate inhibitor of and substrate for **CYP3A4/5**. **In Vivo:** Veledimex generally has moderate to low oral bioavailability after a single oral administration in mice and monkeys (-56% in mice and up to 17.4% in cynomolgus monkeys) with mostly low plasma clearance (1399 and 1170 mL/h per kilogram in mice and monkeys, respectively), high volume of distribution (20271 and 9180 mL/h per kilogram in mice and monkeys, respectively), and long terminal half-lives (-10 hours in mice and -30 hours in monkeys) after intravenous administration<sup>[1]</sup>. Ad-RTS-mIL-12 + veledimex have demonstrated a dose-related increase in tumor IL-12 mRNA and IL-12 protein expression. Discontinuation of veledimex resulted in a return to baseline IL-12 mRNA and protein expression in numerous syngeneic mouse tumor models. Veledimex crosses the blood-brain-barrier in both naive and orthotopic GL-261 mice with increased brain tissue level of -6 fold observed in tumor bearing vs. normal mice. Ad-RTS-mIL-12 + veledimex demonstrate a dose-related increase in survival without significant adverse events<sup>[2]</sup>.

### References:

[1]. Cai H, et al. Plasma Pharmacokinetics of Veledimex, a Small-Molecule Activator Ligand for a Proprietary Gene Therapy Promoter System, in Healthy Subjects. *Clin Pharmacol Drug Dev.* 2017 May;6(3):246-257.

[2]. John A. Barrett, INTRATUMORAL REGULATED EXPRESSION OF IL-12 AS A GENE THERAPY APPROACH TO TREATMENT OF GLIOMA. *Neuro Oncol.* 2015 Nov; 17(Suppl 5): v113.

### CAIndexNames:

Benzoic acid, 2-ethyl-3-methoxy-, 2-(3,5-dimethylbenzoyl)-2-[(1S)-1-(1,1-dimethylethyl)butyl]hydrazide

### SMILES:

O=C(NN(C(C1=CC(C)=CC(C)=C1)=O)[C@H](C(C)(C)C)CC)C2=CC=CC(OC)=C2C

**Caution: Product has not been fully validated for medical applications. For research use only.**

Tel: 732-484-9848 Fax: 888-484-5008 E-mail: sales@ChemScene.com

Address: 1 Deer Park Dr, Suite Q, Monmouth Junction, NJ 08852, USA